Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies

Medical Oncology, Год журнала: 2024, Номер 41(2)

Опубликована: Янв. 9, 2024

Язык: Английский

---

Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies

Nanoscale Advances, Год журнала: 2024, Номер 6(9), С. 2270 - 2286

Опубликована: Янв. 1, 2024

Breast cancer is a global health challenge with staggering statistics underscoring its pervasive impact. The burden of this disease measured in terms prevalence and the challenges it poses to healthcare systems, necessitating closer look at epidemiology Current breast treatments, including surgery, chemotherapy, radiation therapy, targeted therapies, have made significant strides improving patient outcomes. However, they are not without limitations, often leading adverse effects development drug resistance. This comprehensive review delves into complex landscape cancer, incidence, current treatment modalities, inherent limitations existing therapeutic approaches. It also sheds light on promising role nanotechnology, encompassing both inorganic organic nanoparticles equipped ability selectively deliver agents tumor sites, battle against cancer. addresses emerging their associated challenges, future prospects delivery management.

Язык: Английский

---

Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges

Molecular Cancer, Год журнала: 2025, Номер 24(1)

Опубликована: Янв. 18, 2025

Clinically, multimodal therapies are adopted worldwide for the management of cancer, which continues to be a leading cause death. In recent years, immunotherapy has firmly established itself as new paradigm in cancer care that activates body's immune defense cope with cancer. Immunotherapy resulted significant breakthroughs treatment stubborn tumors, dramatically improving clinical outcome patients. Multiple forms immunotherapy, including checkpoint inhibitors (ICIs), adoptive cell therapy and vaccines, have become widely available. However, effectiveness these immunotherapies is not much satisfying. Many patients do respond disease recurrence appears unavoidable because rapidly evolving resistance. Moreover, can give rise severe off-target immune-related adverse events. Strategies remove hindrances mainly focus on development combinatorial or exploitation novel immunotherapeutic mediations. Nanomaterials carrying anticancer agents target site considered practical approaches treatment. Nanomedicine combined offers possibility potentiate systemic antitumor immunity facilitate selective cytotoxicity against cells an effective safe manner. A myriad nano-enabled currently under investigation. Owing gaps between preclinical studies, nano-immunotherapy faces multiple challenges, biosafety nanomaterials trial design. this review, we provide overview summarize evidence indicating how nanomedicine-based increase efficacy immunotherapies. We also discuss key challenges emerged era nanotechnology-based immunotherapy. Taken together, combination drawing increasing attention, it anticipated will achieve desired success therapy.

Язык: Английский

---

Resistance to Trastuzumab

Cancers, Год журнала: 2022, Номер 14(20), С. 5115 - 5115

Опубликована: Окт. 19, 2022

One of the most impactful biologics for treatment breast cancer is humanized monoclonal antibody, trastuzumab, which specifically recognizes HER2/neu (HER2) protein encoded by ERBB2 gene. Useful both advanced and early cancers, trastuzumab has multiple mechanisms action. Classical attributed to action include cell cycle arrest, induction apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC). Recent studies have identified role adaptive immune system in clinical actions trastuzumab. Despite action, many patients demonstrate resistance, primary or adaptive. Newly molecular cellular resistance suppression, vascular mimicry, generation stem cells, deregulation long non-coding RNAs, metabolic escape. These newly are discussed detail this review, particularly considering how they may lead development well-rationalized, patient-tailored combinations that improve patient survival.

Язык: Английский

---

Recent Progress in Immunotherapy for Gastric Cancer

Journal of the Korean Gastric Cancer Association, Год журнала: 2023, Номер 23(1), С. 207 - 207

Опубликована: Янв. 1, 2023

Gastric cancer (GC) is the fourth leading cause of cancer-related deaths worldwide. Under standard care, patients with advanced GC (AGC) have a median survival time approximately 12-15 months. With emergence immunotherapy as key therapeutic strategy in medical oncology, relevant changes are expected systemic treatment GC. In phase III ATTRACTION-2 trial, nivolumab, monoclonal anti-programmed cell death 1 (PD-1) antibody, third- or later-line improved overall (OS) compared placebo AGC. Furthermore, nivolumab combination 5-fluorouracil and platinum first-line OS human epidermal growth factor receptor-2 (HER2)-negative AGC global CheckMate-649 study. Another anti-PD-1 pembrolizumab, trastuzumab cytotoxic chemotherapy treatment, significantly response rate HER2-positive Therefore, immune checkpoint inhibitors (ICIs) essential components current Subsequent treatments after ICI therapy, such rechallenge therapy agents having other modes action, being actively investigated to date. On basis success AGC, various clinical trials underway apply this perioperative postoperative settings for early This review describes recent progress potential biomarkers

Язык: Английский

---

Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions

Pharmaceutics, Год журнала: 2023, Номер 15(10), С. 2402 - 2402

Опубликована: Сен. 28, 2023

Monoclonal therapeutic antibodies have revolutionized the treatment of cancer and other diseases. Fc engineering aims to enhance effector functions or half-life by modifying their regions. Recent advances in modern can be considered next generation antibody therapy. Various strategies are employed, including altering glycosylation patterns via glycoengineering introducing mutations region, thereby enhancing receptor complement interactions. Further, enable bispecific IgG-based heterodimeric antibodies. As techniques continue evolve, an expanding portfolio Fc-engineered is advancing through clinical development, with several already approved for medical use. Despite plethora Fc-based that been analyzed vitro vivo models, we focus here this review on relevant finetune functions, modify stabilize asymmetric IgGs.

Язык: Английский

---

Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies

Structure, Год журнала: 2024, Номер 32(5), С. 536 - 549.e5

Опубликована: Март 8, 2024

Язык: Английский

---

CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation

Journal for ImmunoTherapy of Cancer, Год журнала: 2024, Номер 12(2), С. e008155 - e008155

Опубликована: Фев. 1, 2024

The antitumor activity of natural killer (NK) cells can be enhanced by specific targeting with therapeutic antibodies that trigger antibody-dependent cell-mediated cytotoxicity (ADCC) or genetic engineering to express chimeric antigen receptors (CARs). Despite antibody CAR targeting, some tumors remain resistant towards NK cell attack. While the importance ICAM-1/LFA-1 interaction for is known, its impact on ADCC induced ErbB2 (HER2)-specific trastuzumab and ErbB2-CAR-mediated against breast cancer has not been investigated. Here we used NK-92 expressing high-affinity Fc receptor FcγRIIIa in combination ErbB2-CAR engineered (NK-92/5.28.z) as well primary human combined modified tested varying ICAM-1 expression alternatively blocked LFA-1 cells. Furthermore, specifically stimulated receptor, and/or study their crosstalk at immunological synapse contribution degranulation intracellular signaling antibody-targeted CAR-targeted Blockade absence significantly reduced killing cytokine release during trastuzumab-mediated ErbB2-positive cells, but so Pretreatment 5-aza-2'-deoxycytidine upregulation reversed resistance ADCC. Trastuzumab alone did sufficiently activate required additional co-stimulation, while activation CAR-NK efficient independent LFA-1. Total internal reflection fluorescence single molecule imaging revealed formed an irregular tumor excluded ICAM-1, typical peripheral supramolecular cluster (pSMAC) structures. Mechanistically, affect cell-cell adhesion ADCC, rather resulted decreased via Pyk2 ERK1/2, which was intrinsically provided CAR-mediated targeting. stimulation inhibitory checkpoint NKG2A markedly FcγRIIIa/LFA-1-mediated degranulation, retargeting only marginally affected. Downregulation a critical escape mechanism from trastuzumab-triggered In contrast, are able overcome caused reduction, highlighting potential immunotherapy.

Язык: Английский

---

Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H₂Mab-250/H₂CasMab-2 for Breast Cancers

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Год журнала: 2024, Номер 43(2), С. 35 - 43

Опубликована: Апрель 1, 2024

Overexpression of human epidermal growth factor receptor 2 (HER2) in breast and gastric cancers is an important target for monoclonal antibody (mAb) therapy. All therapeutic mAbs, including anti-HER2 exhibit adverse effects probably due to the recognition antigens expressed normal cells. Therefore, tumor-selective or specific mAbs can be beneficial reducing effects. In this study, we established a novel cancer-specific antibody, named H

Язык: Английский

---

A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms

Cardiovascular Drugs and Therapy, Год журнала: 2024, Номер unknown

Опубликована: Март 16, 2024

Abstract While oncotherapy has made rapid progress in recent years, side effects of anti-cancer drugs and treatments have also come to the fore. These include cardiotoxicity, which can cause irreversible cardiac damages with long-term morbidity mortality. Despite continuous in-depth research on drugs, an improved knowledge underlying mechanisms cardiotoxicity are necessary for early detection management risk. Although most reviews focus cardiotoxic effect a specific individual chemotherapeutic agent, aim our review is provide comprehensive insight into various agents that induced their mechanisms. Characterization these underpinned by animal models clinical studies. In order gain complex mechanisms, we emphasize role inflammatory processes oxidative stress chemotherapy-induced changes. A better understanding identification interplay between chemotherapy inflammatory/oxidative hold some promise prevent or at least mitigate cardiotoxicity-associated mortality among cancer survivors.

Язык: Английский

---